What is Imaxio?
Imaxio operates as an integrated biotechnology company with a strong focus on immunology. The company's core asset is a pipeline of vaccines, encompassing marketed products, clinical-stage candidates, and preclinical-stage projects. Its flagship marketed pharmaceutical is a vaccine against human leptospirosis, currently available in France. The R&D pipeline is built upon the proprietary IMX313 technology platform, which involves antigen re-engineering to enhance immunogenicity. This platform underpins two clinical-stage projects and several preclinical candidates aimed at creating more effective vaccines and immunotherapies. Imaxio's strategic objective is to advance its R&D projects through Phase I/II clinical trials before out-licensing them to biopharmaceutical partners for Phase III development and commercialization. The company also actively seeks collaborations with partners looking to leverage its technology to improve immune responses against poorly immunogenic antigens. Founded in 2000 as a spin-off from the Medical Research Council and the University of Cambridge, Imaxio has a solid foundation in scientific research and development.
How much funding has Imaxio raised?
Imaxio has raised a total of $11.9M across 3 funding rounds:
Unspecified
$4M
Grant
$7.2M
Grant
$772K
Unspecified (2012): $4M, investors not publicly disclosed
Grant (2013): $7.2M led by Jenner Institute
Grant (2014): $772K supported by Agence nationale de la recherche ANR
Key Investors in Imaxio
Agence nationale de la recherche ANR
The ANR is the French national agency responsible for funding project-based research across various scientific disciplines. It supports a wide array of research initiatives, particularly those aimed at sustainable development, and facilitates collaborations both nationally and internationally.
Jenner Institute
The Jenner Institute was founded in November 2005 to develop innovative vaccines against major global diseases. It focuses on both human and livestock diseases, testing new vaccine approaches in parallel in different species, with a major theme of translational research involving rapid early-stage development and assessment of new vaccines in clinical trials.
What's next for Imaxio?
The recent major strategic investment in Imaxio signals a pivotal moment for the company's growth trajectory. With a clear strategy to advance its vaccine and immunotherapy pipeline through early-stage clinical trials and subsequent out-licensing, this capital infusion is expected to accelerate R&D efforts. The company's focus on its IMX313 technology platform suggests a continued emphasis on innovation in vaccine development. Future endeavors will likely involve forging strategic partnerships to bring its promising candidates to market, further solidifying its position in the competitive biotech landscape.
See full Imaxio company page
